An arrangement between Roche Holding Ltd and Novartis AG to increase the sales of an expensive drug in Italy can be considered in breach of EU competition rules, the EU’s top court ruled Tuesday, January 23.
The two Swiss pharmaceutical companies are said to have worked together to discourage doctors from prescribing Roche’s anti-cancer drug Avastin to treat eye diseases, recommending the much more expensive alternative, Lucentis, which is marketed by Novartis.
In 2014, Italy’s competition authority fined the companies each about €90 million (US$110.7 million) over the practice, but the ruling was challenged and Italian appeal judges asked the EU Court of Justice for an opinion on the case.
EU judges said the two companies may be considered guilty of “a restriction of competition,” but said that the final decision on whether to uphold fines against them rests on Italian administrative courts.
Full Content: Courthouse News Service
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Colorado Makes History: First State to Enact Comprehensive AI Legislation
May 14, 2024 by
CPI
Class Action Settlement Reached in Cheerleading Monopoly
May 14, 2024 by
CPI
DOJ Nears Antitrust Lawsuit Against Live Nation
May 14, 2024 by
CPI
Chile Proposes Legislation to Regulate Artificial Intelligence
May 14, 2024 by
CPI
Proposed NCAA Antitrust Settlement in the Works, Says Attorney
May 14, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI